Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:NOVN
- CUSIP: N/A
- Web: www.novantherapeutics.com
Capitalization:- Market Cap: $86.31 million
- Outstanding Shares: 15,984,000
Average Prices:- 50 Day Moving Avg: $6.31
- 200 Day Moving Avg: $6.31
- 52 Week Range: $3.52 - $30.90
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.96
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $768,999.00
- Price / Sales: 112.24
- Book Value: $0.74 per share
- Price / Book: 7.30
Profitability:- EBIDTA: ($49,040,000.00)
- Return on Equity: -194.61%
- Return on Assets: -99.61%
Debt:- Current Ratio: 1.97%
- Quick Ratio: 1.97%
Misc:- Average Volume: 117,057 shs.
- Short Ratio: 1.71
Frequently Asked Questions for Novan (NASDAQ:NOVN)
What is Novan's stock symbol?
Novan trades on the NASDAQ under the ticker symbol "NOVN."
How were Novan's earnings last quarter?
Novan Inc (NASDAQ:NOVN) released its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.24. The business earned $0.10 million during the quarter, compared to analysts' expectations of $10.80 million. View Novan's Earnings History.
When will Novan make its next earnings announcement?
Where is Novan's stock going? Where will Novan's stock price be in 2017?
4 equities research analysts have issued 12 month price targets for Novan's shares. Their forecasts range from $8.00 to $31.00. On average, they expect Novan's share price to reach $17.24 in the next twelve months. View Analyst Ratings for Novan.
Who are some of Novan's key competitors?
Some companies that are related to Novan include Fate Therapeutics (FATE), Viralytics (VRACY), OncoMed Pharmaceuticals (OMED), Vascular Biogenics (VBLT), Obalon Therptcs (OBLN), Cempra (CEMP), Adamis Pharmaceuticals Corporation (ADMP), Vericel Corporation (VCEL), Recro Pharma (REPH), Cogentix Medical (CGNT), Conatus Pharmaceuticals (CNAT), ConforMIS (CFMS), VBI Vaccines (VBIV), Summit Therapeutics PLC (SMMT), ProQR Therapeutics N.V. (PRQR), BioDelivery Sciences International (BDSI), Redhill Biopharma (RDHL) and Adocia (ADOCY).
Who are Novan's key executives?
Novan's management team includes the folowing people:
- Robert A. Ingram, Independent Chairman of the Board
- Nathan Stasko Ph.D., President, Chief Scientific Officer, Director
- G. Kelly Martin, Interim Chief Executive Officer, Director
- William L. Hodges CPA, Interim Chief Financial Officer, Princiapl Financial Officer, Principal Accounting Officer
- Stanley Hollenbach J.D., Senior Vice President - Research and Development
- Jeff N. Hunter, Vice President - Technical Operations
- Paula Brown Stafford, Chief Development Officer, Director
- Brian M Johnson, Chief Commercial Officer
- W. Kent Geer, Independent Director
- Robert J. Keegan, Independent Director
When did Novan IPO?
(NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who owns Novan stock?
Novan's stock is owned by many different of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (1.99%), Vanguard Group Inc. (1.22%), Prospera Financial Services Inc (0.17%) and Goldman Sachs Group Inc. (0.16%). Company insiders that own Novan stock include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.
Who sold Novan stock? Who is selling Novan stock?
Who bought Novan stock? Who is buying Novan stock?
Novan's stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc. and Vanguard Group Inc.. Company insiders that have bought Novan stock in the last two years include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Insider Buying and Selling for Novan.
How do I buy Novan stock?
Shares of Novan can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novan's stock price today?
One share of Novan stock can currently be purchased for approximately $5.40.
MarketBeat Community Rating for Novan (NASDAQ NOVN)MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Novan (NASDAQ:NOVN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $17.24 (219.31% upside) |
Analysts' Ratings History for Novan (NASDAQ:NOVN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/3/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | | Low |  |
| 4/12/2017 | Wedbush | Reiterated Rating | Neutral | $8.00 | High | |
| 10/17/2016 | Credit Suisse Group | Initiated Coverage | Outperform | $27.00 -> $18.97 | N/A | |
| 10/17/2016 | JMP Securities | Initiated Coverage | Outperform | $31.00 | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Novan (NASDAQ:NOVN)Earnings History by Quarter for Novan (NASDAQ NOVN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | | | | | | | |
| 5/12/2017 | Q1 2017 | ($0.49) | ($0.73) | $10.80 million | $0.10 million | View | N/A | |
| 3/20/2017 | Q4 16 | ($1.14) | ($0.82) | | | View | N/A | |
| 11/14/2016 | Q3 16 | ($1.40) | ($5.76) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Novan (NASDAQ:NOVN)2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.26)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.19) | ($0.19) | ($0.19) |
| Q2 2017 | 1 | ($0.67) | ($0.67) | ($0.67) |
| Q3 2017 | 1 | ($0.32) | ($0.32) | ($0.32) |
| Q4 2017 | 1 | ($0.29) | ($0.29) | ($0.29) |
| Q1 2018 | 1 | ($0.21) | ($0.21) | ($0.21) |
| Q2 2018 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q3 2018 | 1 | ($0.35) | ($0.35) | ($0.35) |
| Q4 2018 | 1 | ($0.43) | ($0.43) | ($0.43) |
(Data provided by Zacks Investment Research)
Dividend History for Novan (NASDAQ:NOVN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Novan (NASDAQ:NOVN)Insider Ownership Percentage: 10.72%
Institutional Ownership Percentage: 6.05%
Insider Trades by Quarter for Novan (NASDAQ:NOVN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/29/2017 | Robert Alexander Ingram | Director | Buy | 12,000 | $4.57 | $54,840.00 | |
| 8/23/2017 | John W Palmour | Director | Buy | 12,000 | $3.99 | $47,880.00 | |
| 9/26/2016 | Life Sciences Holdings L Malin | Major Shareholder | Buy | 800,000 | $11.00 | $8,800,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Novan (NASDAQ:NOVN)
Latest Headlines for Novan (NASDAQ:NOVN)
| Source: |
|
Novan (NOVN) Chart for Sunday, September, 24, 2017
